SCHEDULE 13G/A: Italian Investor Group Discloses 6.49% Stake in Quince Therapeutics
Beneficial Ownership Report
Genextra S.p.A., along with its CEO Francesco Micheli and attorney-in-fact Matteo Bruno Renzulli, has disclosed a beneficial ownership of 6.49% in Quince Therapeutics, Inc. common stock.
Summary
- Genextra S.p.A., an Italian entity, along with its Chief Executive Officer Francesco Micheli and attorney-in-fact Matteo Bruno Renzulli, have jointly filed an Amendment No. 1 to Schedule 13G.
- The filing discloses beneficial ownership of 2,806,611 shares of Quince Therapeutics, Inc. common stock.
- This represents 6.49% of the total outstanding common stock of Quince Therapeutics, Inc.
- The percentage is calculated based on 43,276,606 shares outstanding as of September 30, 2024, as reported by Quince Therapeutics in its Form 10-Q filed on November 13, 2024.
- Genextra S.p.A. holds sole dispositive power over these shares, with decisions related to dispositions approved by its board of directors.
- Francesco Micheli and Matteo Bruno Renzulli share voting power over the shares, with individual voting decisions possible by either.
- The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a neutral, factual regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional shareholder's stake and voting/dispositive powers.
Key Dates
| Date | Description |
|---|---|
| 06/15/2022 | Date Matteo Bruno Renzulli was appointed attorney in fact (procuratore speciale) of Genextra S.p.A. |
| 09/30/2024 | Date as of which Quince Therapeutics, Inc. reported 43,276,606 common shares outstanding in its Form 10-Q |
| 10/18/2024 | Date of event which requires filing of this statement |
| 11/13/2024 | Date Quince Therapeutics, Inc. filed its Quarterly Report on Form 10-Q disclosing shares outstanding |
| 02/14/2025 | Date of filing and signing of the Schedule 13G Amendment No. 1 |
Keywords
Quince Therapeutics, Genextra S.p.A., Francesco Micheli, Matteo Bruno Renzulli, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.